Leflunomida Pharmathen

Leflunomide, the active ingredient in Leflunomida Pharmathen, is a disease-modifying antirheumatic drug (DMARD) presented as a tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunomida Pharmathen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a DMARD that modulates autoimmune pathways in inflammatory arthritis.

Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage. Psoriatic arthritis: improves both skin lesions and joint symptoms. Active disease in adults: helps achieve clinical remission and functional improvement.

Leflunomida Pharmathen may cause a range of adverse reactions.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Rash: skin irritation or erythema. - Elevated liver enzymes: mild transaminase rise. - Hypertension: increase in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: potential hepatic failure. - Bone marrow suppression: pancytopenia or anemia. - Pulmonary toxicity: interstitial lung disease. - Stevens‑Johnson syndrome: severe skin reaction. - Teratogenicity: risk of fetal malformations. - Severe infections: opportunistic bacterial or viral infections.

Before initiating therapy, several safety considerations are required. - Liver monitoring: perform baseline and periodic liver function tests. - Blood pressure: monitor regularly, especially in hypertensive patients. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Infection risk: assess for active infections and avoid live vaccines. - Hematology: check complete blood count before and during treatment. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Statins: heightened risk of myopathy and rhabdomyolysis. - Azathioprine: additive bone‑marrow suppression. - Live vaccines: may cause severe infection.

Moderate Interactions (Monitor Closely): - NSAIDs: potential additive hepatotoxicity. - ACE inhibitors: possible exacerbation of hypertension. - Oral contraceptives: reduced hormonal efficacy, consider alternative contraception.